title: A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
abstract: The response to neoadjuvant chemotherapy has been proven to predict long-term clinical benefits for patients. Our research is to construct a nomogram to predict pathological complete response of human epidermal growth factor receptor 2 negative breast cancer patients.
  
  
  
  We enrolled 815 patients who received neoadjuvant chemotherapy from 2003 to 2015 and divided them into a training set and a validation set. Univariate logistic regression was performed to screen for predictors and construct the nomogram; multivariate logistic regression was performed to identify independent predictors.
  
  
  
  After performing the univariate logistic regression analysis in the training set, tumor size, hormone receptor status, regimens of neoadjuvant chemotherapy and cycles of neoadjuvant chemotherapy were the final predictors for the construction of the nomogram. The multivariate logistic regression analysis demonstrated that T4 status, hormone receptor status and receiving regimen of paclitaxel and carboplatin were independent predictors of pathological complete response. The area under the receiver operating characteristic curve of the training set and the validation set was 0.779 and 0.701, respectively.
  
  
  
  We constructed and validated a nomogram to predict pathological complete response in human epidermal growth factor receptor 2 negative breast cancer patients. We also identified tumor size, hormone receptor status and paclitaxel and carboplatin regimen as independent predictors of pathological complete response.
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Xi
authors: X
authors: Jin
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yizhoujiang@fudan.edu.cn.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yizhoujiang@fudan.edu.cn.
authors: Yi-Zhou
authors: YZ
authors: Jiang
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Sheng
authors: S
authors: Chen
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Ke-Da
authors: KD
authors: Yu
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Ding
authors: D
authors: Ma
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Wei
authors: W
authors: Sun
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Zhi-Min
authors: ZM
authors: Shao
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. didy@medmail.com.cn.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. didy@medmail.com.cn.
authors: Gen-Hong
authors: GH
authors: Di
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019540:Area Under Curve; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D049451:Nomograms; D012372:ROC Curve; D018719:Erb-b2 Receptor Tyrosine Kinases; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: HER2 negative breast cancer; Neoadjuvant chemotherapy; Nomogram; Pathological complete response